Summary
14.50 -0.13(-0.89%)09/06/2024
Avadel Pharmaceuticals plc (AVDL)
Avadel Pharmaceuticals plc (AVDL)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| -0.65 | -4.45 | -12.76 | -4.89 | -11.18 | 9.73 | 519.44 | 23.36 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 14.50 | |
| Open | 14.72 | |
| High | 14.93 | |
| Low | 14.38 | |
| Volume | 1,025,493 | |
| Change | -0.10 | |
| Change % | -0.65 | |
| Avg Volume (20 Days) | 852,236 | |
| Volume/Avg Volume (20 Days) Ratio | 1.20 | |
| 52 Week Range | 9.50 - 19.09 | |
| Price vs 52 Week High | -24.07% | |
| Price vs 52 Week Low | 52.58% | |
| Range | -1.53 | |
| Gap Up/Down | -0.08 | |
Fundamentals | ||
| Market Capitalization (Mln) | 1,395 | |
| EBIDTA | -38,869,000 | |
| PE Ratio | 0.0000 | |
| PEG Ratio | 0.0700 | |
| WallStreet Target Price | 17.95 | |
| Book Value | 1.6880 | |
| Earnings Per Share | -1.1350 | |
| EPS Estimate Current Quarter | -0.3800 | |
| EPS Estimate Next Quarter | -0.3700 | |
| EPS Estimate Current Year | -1.3700 | |
| EPS Estimate Next Year | -1.0500 | |
| Diluted EPS (TTM) | -1.1350 | |
| Revenues | ||
| Profit Marging | 0.0000 | |
| Operating Marging (TTM) | 0.0000 | |
| Return on asset (TTM) | -0.1621 | |
| Return on equity (TTM) | -0.4909 | |
| Revenue TTM | 0 | |
| Revenue per share TTM | 0.0000 | |
| Quarterly Revenue Growth (YOY) | -1.0000 | |
| Quarterly Earnings Growth (YOY) | 0.0000 | |
| Gross Profit (TTM) | 16,592,000 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 0.0000 | |
| Forward PE | 0.0000 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 4.5319 | |
| Revenue Enterprise Value | 38.1481 | |
| EBITDA Enterprise Value | 158.6777 | |
| Shares | ||
| Shares Outstanding | 58,620,100 | |
| Shares Float | 46,081,251 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.00 | |
| Insider (%) | 1.07 | |
| Institutions (%) | 55.28 | |
09/03 08:00 EST - globenewswire.com
Avadel Pharmaceuticals Announces Publication of RESTORE Data Highlighting Challenges with Twice-Nightly Oxybates and Strong Patient Preference for Once-Nightly LUMRYZ™ Dosing (sodium oxybate) Extended-Release Oral Suspension (CIII)
– Survey data demonstrate 94% of people with narcolepsy prefer the once-nightly regimen of LUMRYZ over twice-nightly oxybate regimens –
Avadel Pharmaceuticals Announces Publication of RESTORE Data Highlighting Challenges with Twice-Nightly Oxybates and Strong Patient Preference for Once-Nightly LUMRYZ™ Dosing (sodium oxybate) Extended-Release Oral Suspension (CIII)
– Survey data demonstrate 94% of people with narcolepsy prefer the once-nightly regimen of LUMRYZ over twice-nightly oxybate regimens –
08/28 08:00 EST - globenewswire.com
Avadel Pharmaceuticals to Present at Upcoming Investor Conferences
DUBLIN, Ireland, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that members of management will participate in the following upcoming investor conferences:
Avadel Pharmaceuticals to Present at Upcoming Investor Conferences
DUBLIN, Ireland, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that members of management will participate in the following upcoming investor conferences:
08/09 12:27 EST - seekingalpha.com
Avadel Pharmaceuticals plc (AVDL) Q2 2024 Earnings Call Transcript
Avadel Pharmaceuticals plc (NASDAQ:AVDL ) Q2 2024 Earnings Conference Call August 8, 2024 8:30 AM ET Company Participants Austin Murtagh - Director, Precision AQ Greg Divis - Chief Executive Officer Richard Kim - Chief Commercial Officer Jennifer Gudeman - Senior Vice President, Medical & Clinical Affairs Tom McHugh - Chief Financial Officer Conference Call Participants Andrew Tsai - Jefferies François Brisebois - Oppenheimer Ami Fadia - Needham & Company David Amsellem - Piper Sandler Marc Goodman - Leerink Fatima Amanat - UBS Oren Livnat - H.C. Wainwright Myriam Belghiti - LifeSci Capital Matt Kaplan - Ladenburg Thalmann Brandon Folkes - Rodman & Renshaw Operator Greetings, and welcome to Avadel Pharmaceuticals' Second Quarter 2024 Earnings Call.
Avadel Pharmaceuticals plc (AVDL) Q2 2024 Earnings Call Transcript
Avadel Pharmaceuticals plc (NASDAQ:AVDL ) Q2 2024 Earnings Conference Call August 8, 2024 8:30 AM ET Company Participants Austin Murtagh - Director, Precision AQ Greg Divis - Chief Executive Officer Richard Kim - Chief Commercial Officer Jennifer Gudeman - Senior Vice President, Medical & Clinical Affairs Tom McHugh - Chief Financial Officer Conference Call Participants Andrew Tsai - Jefferies François Brisebois - Oppenheimer Ami Fadia - Needham & Company David Amsellem - Piper Sandler Marc Goodman - Leerink Fatima Amanat - UBS Oren Livnat - H.C. Wainwright Myriam Belghiti - LifeSci Capital Matt Kaplan - Ladenburg Thalmann Brandon Folkes - Rodman & Renshaw Operator Greetings, and welcome to Avadel Pharmaceuticals' Second Quarter 2024 Earnings Call.
08/05 11:01 EST - zacks.com
Does Avadel (AVDL) Have the Potential to Rally 43.6% as Wall Street Analysts Expect?
The mean of analysts' price targets for Avadel (AVDL) points to a 43.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Does Avadel (AVDL) Have the Potential to Rally 43.6% as Wall Street Analysts Expect?
The mean of analysts' price targets for Avadel (AVDL) points to a 43.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
06/27 16:05 EST - globenewswire.com
Avadel Pharmaceuticals to Join Russell 3000® Index
DUBLIN, June 27, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it is set to join the broad-market Russell 3000® Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, effective at the open of US equity markets on Monday, July 1, 2024, according to a preliminary list of additions posted Friday, May 24, 2024.
Avadel Pharmaceuticals to Join Russell 3000® Index
DUBLIN, June 27, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it is set to join the broad-market Russell 3000® Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, effective at the open of US equity markets on Monday, July 1, 2024, according to a preliminary list of additions posted Friday, May 24, 2024.
05/22 08:00 EST - globenewswire.com
Avadel Pharmaceuticals Shares New LUMRYZ™ (sodium oxybate) For Extended-release Oral Suspension (CIII) Data at SLEEP 2024
– 11 accepted abstracts, including new data reiterating satisfaction, preference and clinical benefit of LUMRYZ –
Avadel Pharmaceuticals Shares New LUMRYZ™ (sodium oxybate) For Extended-release Oral Suspension (CIII) Data at SLEEP 2024
– 11 accepted abstracts, including new data reiterating satisfaction, preference and clinical benefit of LUMRYZ –
05/21 07:00 EST - globenewswire.com
Avadel Pharmaceuticals Appoints Naseem Amin, M.D. to its Board of Directors
DUBLIN, Ireland, May 21, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today the appointment of Naseem Amin, M.D. to its board of directors, effective May 17, 2024. Dr. Amin, a highly successful executive who brings global industry and leadership experience to Avadel, currently serves as Chief Executive Officer of Orphalan SA.
Avadel Pharmaceuticals Appoints Naseem Amin, M.D. to its Board of Directors
DUBLIN, Ireland, May 21, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today the appointment of Naseem Amin, M.D. to its board of directors, effective May 17, 2024. Dr. Amin, a highly successful executive who brings global industry and leadership experience to Avadel, currently serves as Chief Executive Officer of Orphalan SA.
05/08 07:00 EST - globenewswire.com
Avadel Pharmaceuticals Provides Corporate Update and Reports First Quarter 2024 Financial Results
-- Generated $27.2 million in net revenue from sales of LUMRYZ™ -- -- Through March 31, greater than 2,800 patients enrolled in Avadel's RYZUP patient support services and more than 1,700 patients initiated therapy --
Avadel Pharmaceuticals Provides Corporate Update and Reports First Quarter 2024 Financial Results
-- Generated $27.2 million in net revenue from sales of LUMRYZ™ -- -- Through March 31, greater than 2,800 patients enrolled in Avadel's RYZUP patient support services and more than 1,700 patients initiated therapy --
05/01 08:00 EST - globenewswire.com
Avadel Pharmaceuticals to Provide a Corporate Update and Report First Quarter 2024 Financial Results on May 8
DUBLIN, Ireland, May 01, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it will host a conference call and live webcast at 8:30 a.m. ET on Wednesday, May 8, 2024, to provide a corporate update and discuss the Company's financial results for the first quarter ended March 31, 2024.
Avadel Pharmaceuticals to Provide a Corporate Update and Report First Quarter 2024 Financial Results on May 8
DUBLIN, Ireland, May 01, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it will host a conference call and live webcast at 8:30 a.m. ET on Wednesday, May 8, 2024, to provide a corporate update and discuss the Company's financial results for the first quarter ended March 31, 2024.
04/29 10:56 EST - zacks.com
Wall Street Analysts Predict a 28.58% Upside in Avadel (AVDL): Here's What You Should Know
The average of price targets set by Wall Street analysts indicates a potential upside of 28.6% in Avadel (AVDL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Wall Street Analysts Predict a 28.58% Upside in Avadel (AVDL): Here's What You Should Know
The average of price targets set by Wall Street analysts indicates a potential upside of 28.6% in Avadel (AVDL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
04/02 03:40 EST - seekingalpha.com
Avadel Pharmaceuticals: A Deep Dive Into Lumryz's Once-Nightly Revolution
Avadel Pharmaceuticals reports strong Q4 2023 earnings for Lumryz, its once-nightly formulation of sodium oxybate for narcolepsy. Lumryz fills a significant gap in narcolepsy treatment by offering a more patient-friendly dosing schedule and improving compliance and patient outcomes. Legal developments, including a favorable jury ruling on patent litigation, reduce legal overhang and instill investor confidence in Avadel's ability to navigate challenges.
Avadel Pharmaceuticals: A Deep Dive Into Lumryz's Once-Nightly Revolution
Avadel Pharmaceuticals reports strong Q4 2023 earnings for Lumryz, its once-nightly formulation of sodium oxybate for narcolepsy. Lumryz fills a significant gap in narcolepsy treatment by offering a more patient-friendly dosing schedule and improving compliance and patient outcomes. Legal developments, including a favorable jury ruling on patent litigation, reduce legal overhang and instill investor confidence in Avadel's ability to navigate challenges.
04/01 08:00 EST - globenewswire.com
Avadel Pharmaceuticals to Present at the 23rd Annual Needham Healthcare Conference
DUBLIN, Ireland, April 01, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that members of management will participate in a fireside chat at the 23rd Annual Needham Healthcare Conference on Monday, April 8 at 10:15 a.m. ET.
Avadel Pharmaceuticals to Present at the 23rd Annual Needham Healthcare Conference
DUBLIN, Ireland, April 01, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that members of management will participate in a fireside chat at the 23rd Annual Needham Healthcare Conference on Monday, April 8 at 10:15 a.m. ET.
03/04 15:37 EST - globenewswire.com
Avadel Pharmaceuticals Issues Statement On Patent Litigation
DUBLIN, Ireland, March 04, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), today issued a statement in response to a jury ruling from the United States District Court for the District of Delaware (“Court”) in a patent suit brought by Jazz Pharmaceuticals Inc. regarding LUMRYZ™.
Avadel Pharmaceuticals Issues Statement On Patent Litigation
DUBLIN, Ireland, March 04, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), today issued a statement in response to a jury ruling from the United States District Court for the District of Delaware (“Court”) in a patent suit brought by Jazz Pharmaceuticals Inc. regarding LUMRYZ™.
03/04 10:43 EST - seekingalpha.com
Avadel Pharmaceuticals plc (AVDL) Q4 2023 Earnings Call Transcript
Avadel Pharmaceuticals plc (NASDAQ:AVDL ) Q4 2023 Earnings Conference Call March 4, 2024 7:30 AM ET Company Participants Austin Murtagh - Stern IR Gregory Divis - CEO Richard Kim - Chief Commercial Officer Thomas McHugh - CFO Conference Call Participants Francois Brisebois - Oppenheimer Ami Fadia - Needham Andrew Tsai - Jefferies David Amsellem - Piper Sandler Ashwani Verma - UBS Myriam Belghiti - LifeSci Capital Chase Knickerbocker - Craig-Hallum Rudy Li - Leerink Matt Kaplan - Ladenburg Thalmann Oren Livnat - H.C. Wainwright Operator Greetings, and welcome to Avadel Pharmaceuticals Fourth Quarter and Full Year 2023 Earnings Call.
Avadel Pharmaceuticals plc (AVDL) Q4 2023 Earnings Call Transcript
Avadel Pharmaceuticals plc (NASDAQ:AVDL ) Q4 2023 Earnings Conference Call March 4, 2024 7:30 AM ET Company Participants Austin Murtagh - Stern IR Gregory Divis - CEO Richard Kim - Chief Commercial Officer Thomas McHugh - CFO Conference Call Participants Francois Brisebois - Oppenheimer Ami Fadia - Needham Andrew Tsai - Jefferies David Amsellem - Piper Sandler Ashwani Verma - UBS Myriam Belghiti - LifeSci Capital Chase Knickerbocker - Craig-Hallum Rudy Li - Leerink Matt Kaplan - Ladenburg Thalmann Oren Livnat - H.C. Wainwright Operator Greetings, and welcome to Avadel Pharmaceuticals Fourth Quarter and Full Year 2023 Earnings Call.
03/04 06:30 EST - globenewswire.com
Avadel Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results
-- Generated $19.5 million in fourth quarter and $28.0 million of full year 2023 net revenue from sales of LUMRYZ™ -- -- As of January 31 st , greater than 2,200 patients enrolled in RYZUP TM and more than 1,200 patients initiated therapy --
Avadel Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results
-- Generated $19.5 million in fourth quarter and $28.0 million of full year 2023 net revenue from sales of LUMRYZ™ -- -- As of January 31 st , greater than 2,200 patients enrolled in RYZUP TM and more than 1,200 patients initiated therapy --
01/28 02:56 EST - seekingalpha.com
Avadel Pharmaceuticals: Strong Launch Of Lumryz With A Legal Risk Backdrop
Avadel Pharmaceuticals has made good progress with the launch of Lumryz, enrolling 1,900 patients and generating $19 million in Q4 net sales. Legal risks from competitor Jazz Pharmaceuticals remain a concern, with ongoing litigation and the potential for Lumryz to be pulled from the market. Lumryz can capture a significant portion of the narcolepsy market and expand into idiopathic hypersomnia.
Avadel Pharmaceuticals: Strong Launch Of Lumryz With A Legal Risk Backdrop
Avadel Pharmaceuticals has made good progress with the launch of Lumryz, enrolling 1,900 patients and generating $19 million in Q4 net sales. Legal risks from competitor Jazz Pharmaceuticals remain a concern, with ongoing litigation and the potential for Lumryz to be pulled from the market. Lumryz can capture a significant portion of the narcolepsy market and expand into idiopathic hypersomnia.
01/18 11:36 EST - zacks.com
Here's Why You Should Invest in Avadel (AVDL) Stock Now
Here, we discuss some reasons why buying Avadel Pharmaceuticals (AVDL) stock now may turn out to be a prudent move.
Here's Why You Should Invest in Avadel (AVDL) Stock Now
Here, we discuss some reasons why buying Avadel Pharmaceuticals (AVDL) stock now may turn out to be a prudent move.
01/15 13:32 EST - zacks.com
Avadel (AVDL) is a Great Momentum Stock: Should You Buy?
Does Avadel (AVDL) have what it takes to be a top stock pick for momentum investors? Let's find out.
Avadel (AVDL) is a Great Momentum Stock: Should You Buy?
Does Avadel (AVDL) have what it takes to be a top stock pick for momentum investors? Let's find out.